Description

Cosopt (dorzolamide, timolol) Eye Drops Solution 5 ml

Ingredients

Active ingredients: Dorzolamide hydrochloride and Timolol maleate.
Inactive ingredients: Mannitol, carbomer 974P, tyloxapol, edetate disodium, sodium chloride, purified water, and benzalkonium chloride.

Dosage

The usual dose is one drop of Cosopt in the affected eye(s) two times a day. Consult your healthcare provider for the correct dosage.

Indications

Cosopt is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Contraindications

Do not use Cosopt if you are allergic to any of the ingredients, have asthma, severe chronic obstructive pulmonary disease, bradycardia, heart block, or are taking certain medications.

Directions

Shake well before use. Tilt your head back, pull down the lower eyelid, and instill the prescribed number of drops. Close your eyes for 1-2 minutes. Avoid touching the dropper tip to prevent contamination.

Scientific Evidence

Cosopt combines two active ingredients, dorzolamide, and timolol, to effectively lower intraocular pressure. Dorzolamide inhibits carbonic anhydrase, reducing aqueous humor production, while timolol is a non-selective beta-adrenergic antagonist that decreases aqueous humor formation. Clinical studies have shown that the combination of these two agents provides a greater reduction in intraocular pressure compared to monotherapy.

Additional Information

Cosopt may cause blurred vision, eye irritation, or stinging upon administration. It is important to inform your healthcare provider about any existing medical conditions or medications before using Cosopt. Regular eye examinations are necessary while using this medication to monitor for any adverse effects.

Pharmacological studies have demonstrated the efficacy of Cosopt in managing intraocular pressure in patients with glaucoma. Research by Xiong et al. (2019) highlighted the superior efficacy of dorzolamide-timolol combination therapy compared to timolol alone in reducing intraocular pressure over a 12-week period.

Clinical trials have also shown that Cosopt is well-tolerated with a low incidence of systemic side effects. Patients using Cosopt have reported improved compliance due to the convenience of a fixed-combination therapy. Consult your healthcare provider for personalized recommendations and monitoring while using Cosopt.